We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Owen Mumford

Owen Mumford Ltd. is an industry leader in the medical device market with a diverse product range including advanced ... read more Featured Products: More products

Download Mobile App





Owen Mumford Presents Cutting-Edge Capillary Blood Sampling Devices for POC Testing

By LabMedica International staff writers
Posted on 15 Nov 2022
Print article
Image: Unistik Touch safety lancet is designed for seamless capillary blood sampling (Photo courtesy of Owen Mumford)
Image: Unistik Touch safety lancet is designed for seamless capillary blood sampling (Photo courtesy of Owen Mumford)

Owen Mumford (Oxford, UK) is once again exhibiting at this year’s MEDICA in Düsseldorf, Germany where it is presenting tomorrow’s medical device technology today. Attracting several thousand exhibitors from more than 50 countries, MEDICA is the world’s largest event for the medical sector, where each year, leading individuals from the fields of business, research, and politics converge alongside tens of thousands of decision-makers.

At MEDICA 2022, Owen Mumford is showcasing its pioneering products from three different ranges: safety pen needles, venous blood collection set and capillary blood sampling devices. The company’s portfolio of safety pen needles for insulin injections includes the Unifine SafeControl device which is designed to protect healthcare professionals, balancing both safety and control during the injection process. Compatible with all major brands of injection pens, it is available in a variety of sizes and features a manual push tab for easy, one-handed activation of the safety mechanism. It has both a visual and audible confirmation that the safety mechanism has been activated, making it a dual safety pen needle.

Among Owen Mumford’s featured products at MEDICA is its Unistik Touch safety lancet featuring ground-breaking comfort zone technology which helps to minimize the pain of capillary blood sampling. Unistik Touch safety lancet is designed to make capillary sampling as simple and seamless as possible. With one-touch activation, users can simply press the device against the sample site, allowing it to activate automatically under pressure. Once activated, the needle retracts into the body of the device, minimizing the risk of re-use, cross-infection and injury. At MEDICA 2022, Owen Mumford is also showcasing its recently launched venous blood collection portfolio consisting of new devices such as, the Unistik ShieldLock and Unistik VacuFlip. This range provides safety, comfort and quality for healthcare professionals when performing venous blood collection procedures.

Related Links:
Owen Mumford 

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Hemoglobin Testing System
VARIANTnbs

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.